Urovant Sciences Revenue and Competitors

Location

$100M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Urovant Sciences's estimated annual revenue is currently $38.4M per year.(i)
  • Urovant Sciences's estimated revenue per employee is $193,750
  • Urovant Sciences's total funding is $100M.

Employee Data

  • Urovant Sciences has 198 Employees.(i)
  • Urovant Sciences grew their employee count by -42% last year.

Urovant Sciences's People

NameTitleEmail/Phone
1
Area VP, Market Access-Regional Accounts/Long Term Care/GPOReveal Email/Phone
2
National VP, Specialty SalesReveal Email/Phone
3
Area VP Specialty SalesReveal Email/Phone
4
VP Market Access, Account Management & Trade RelationsReveal Email/Phone
5
Head Global Talent AcquisitionReveal Email/Phone
6
VP, Market Access Strategy & MarketingReveal Email/Phone
7
VP, Commercial ManufacturingReveal Email/Phone
8
SVP Global Regulatory AffairsReveal Email/Phone
9
SVP and General Manager, EuropeReveal Email/Phone
10
Associate Director Project ManagementReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Urovant Sciences?

Improving quality-of-life through innovation in urology. Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Urovant is a nimble company with an entrepreneurial focus on improving the way providers and their patients confront urologic diseases that are difficult to treat. Every employee at Urovant plays an integral role to our success. We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve. Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise. Urovant's lead product candidate, vibegron, is a ?3-adrenergic agonist being developed for an oral, once-daily treatment for overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Urovant's second investigational product candidate, URO-902, is a novel gene therapy for patients with overactive bladder symptoms who have failed oral pharmacologic therapy. Overactive bladder (OAB) is a clinical condition characterized by the sudden urge to urinate, with or without accidental urinary leakage, and usually with increased frequency. The exact cause is unknown, making this a difficult condition to treat. In the United States, more than 30 million people over the age of 40 suffer from the bothersome symptoms of OAB1, which can lead to depression and anxiety and have a negative impact on quality of life.2 1. Coyne, et al., EpiLUTS 2007 2. Kinsey D, et al., J Health Psychol. 2016

keywords:N/A

$100M

Total Funding

198

Number of Employees

$38.4M

Revenue (est)

-42%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Urovant Sciences News

2022-04-17 - Urovant Sciences Announces Publication of EMPOWUR Trial ...

Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for areas of unmet need, with a...

2022-04-13 - Urovant Sciences to Present Interim Data from Phase 2a ...

Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for areas of unmet need, with a...

2022-04-06 - CORRECTING and REPLACING Urovant Sciences ...

Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for areas of unmet need, with a...

2019-02-22 - Urovant Sciences Gets $100M In Debt Funding

Irvine-based Urovant Sciences, which is developing biopharmaceuticals for treating urologic conditions, said late Friday afternoon that it has entered into a deal for up to $100M in debt financing, from Hercules Cpaital. According to the company, the new funding will go towards ongoing developme ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$31.6M198-11%N/A
#2
$31.7M199N/AN/A
#3
$33.2M2012%N/A
#4
$40.4M2012%N/A
#5
$35M201N/AN/A